Focused On-demand Library for Synaptosomal-associated protein 29

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O95721

UPID:

SNP29_HUMAN

Alternative names:

Soluble 29 kDa NSF attachment protein; Vesicle-membrane fusion protein SNAP-29

Alternative UPACC:

O95721

Background:

Synaptosomal-associated protein 29 (SNAP-29) plays a pivotal role in cellular processes, including membrane fusion and autophagy. As a member of the SNARE protein family, SNAP-29 facilitates the fusion of autophagosomes with lysosomes, a critical step in autophagy, and is involved in ciliogenesis by regulating membrane fusions. Its alternative names include Soluble 29 kDa NSF attachment protein and Vesicle-membrane fusion protein SNAP-29.

Therapeutic significance:

SNAP-29's involvement in cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome highlights its potential as a therapeutic target. Understanding the role of SNAP-29 could open doors to potential therapeutic strategies for this neurocutaneous syndrome.